An employer could benefit from contemplating its risk management plan regarding the funding of gene and cell therapies. What is the potential financial exposure related to gene and cell therapies for a self-insured employer without stop-loss coverage and how could a partnering manufacturer and/or third-party administrator aid in smoothing a self-insured employer’s costs for gene and cell therapies?

This report was commissioned by bluebird bio, a manufacturer of gene therapies.